A Safety/Efficacy Trial of Zonisamide for Essential Tremor

NCT ID: NCT00223743

Last Updated: 2012-06-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-11-30

Brief Summary

The purpose of this pilot study is to obtain information whether the medication zonisamide reduces tremor in persons with essential tremor and is well tolerated.

Detailed Description

Essential tremor is common, affecting about four percent of the population above age 40 years. Of these, about half have troublesome tremor that warrants medical therapy, but only half of these find satisfactory treatment. Thus it can be estimated that about one million Americans have not been able to find adequate therapy for their essential tremor. Presently used medications may fail due to lack of efficacy or tolerance. After encountering anecdotal experience of zonisamide's efficacy for essential tremor we decided to conduct a single-site open-treatment rising-dose study with blinded videotape ratings of tremor. Zonisamide is presently on the market in the United States for epilepsy. Its use in other conditions is experimental.

Healthy participants with bilateral hand tremor will initially sign an IRB-approved informed consent form, then have assessments in a Screening Visit to determine that they are healthy (physical and neurological examinations, routine blood tests, electrocardiogram) and tremor assessments with rating scales. Tremor at each visit will be videotaped, as well as assessed openly by a rater. If participants meet eligibility criteria, they will return to a Baseline Visit (Visit 1) for repeat tremor assessment and the initial dispensation of zonisamide.

The study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day. During this 12-week dose adjustment phase, the participant will be seen in clinic each 4 weeks for tremor assessments and review of health status. In addition, the participant will be contacted by telephone each week. If any symptom occurs suggestive of side effects, the escalation will be stopped or the dose reduced in order to resolve the symptom.

At the end of the 12-week dose adjustment phase, at Visit 4, it will be determined whether meaningful tremor reduction has occurred at the target dose of 300 mg per day or at a lesser but tolerated dose. If not, the participant will discontinue from the study. If benefit has occurred, the subject will be invited to continue taking zonisamide for another 12 weeks, at the conclusion of which the participant will be seen in the final visit (Visit 5).

The videotapes will be coded so that the order they were made is not apparent, and the degree of tremor will be rated by a rater who does not know the study participants.

Conditions

Essential Tremor

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Zonisamide

Zonisamide administration and tremor assessment to assess efficacy in reducing essential tremor

Group Type: EXPERIMENTAL

Zonisamide

Intervention Type: DRUG

study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.

Interventions

Zonisamide

study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• age 18 or older
• diagnosis of essential tremor
• tremor present in both hands for at least one year
• tremor is bothersome in at least one hand, so that reduction of tremor would improve quality of life
• able to comply with study visits and procedures
• has voluntarily signed consent form
• able to abstain from alcohol for 12 hours prior to each visit, and from caffeine on day prior to visit
• taking no medications or stable doses of anti-tremor medication for 4 weeks prior to the Baseline visit

Exclusion Criteria

• medical condition likely to cause hospitalization during the study
• progressive neurological disorder other than essential tremor
• history of serious psychiatric illness
• history of drug or alcohol abuse in past year
• consumes more than two glasses of wine or equivalent per day
• has received botulinum toxin injection in past 6 months
• currently using experimental device
• has taken experimental drug within 5 half lives of its elimination
• has received deep brain stimulation in past two weeks or has potential need for this therapy during the study
• thalamotomy within the past 6 months
• taking medications judged by investigator to exacerbate tremor
• has probable cause of tremor other than essential tremor
• condition likely to interfere with absorption, metabolism or elimination of study drug
• hepatic disease
• renal disease
• history of renal stones
• history of allergy to sulfonamides

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ralph M. Parsons Foundation

OTHER

Sponsor Role: collaborator

VA Greater Los Angeles Healthcare System

FED

Sponsor Role: lead

Responsible Party

Adrian Handforth, MD

Assistant Chief, Neurology, VAMC

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Adrian Handforth, M.D.

Role: PRINCIPAL_INVESTIGATOR

Veterans Affairs Greater Los Angeles

Locations

VA Greater Los Angeles

Los Angeles, California, United States

Countries

United States

Other Identifiers

0030

Identifier Type: -

Identifier Source: org_study_id